Market news, stock analysis and investing ideas

Candel Slides 26% After Mid-2027 BLA Plan and New $50M Stock Program

Candel said it plans to file its prostate cancer application in mid-2027 and set up a new $50 million at-the-market stock program. Shares closed Nov. 13 at $6.20, 26.1% below the Nov. 12 close.

Candel Slides 26% After Mid-2027 BLA Plan and New $50M Stock Program

Candel Therapeutics, Inc. (NASDAQ: CADL) said in an 8-K filed at 4:05 p.m. ET on Nov. 12, after the close, that it currently plans to submit its prostate cancer Biologics License Application (BLA) to the FDA in mid-2027. The company cited assay refinement and its dialogue with the agency. At 4:22 p.m. it also filed a prospectus supplement for up to $50 million in stock sales.

A later filing date and new share supply, then a partial rebound

Both items landed within about 20 minutes on the evening of Nov. 12, and the stock fell 39.09% in after-hours trading. Candel recovered part of that loss in the Nov. 13 session but still closed at $6.20, 26.1% below its $8.39 close on Nov. 12. The two items arrived together, so the price action cannot separate their effects.

Shares dropped after hours, then climbed through Nov. 13

After-hours trading is the extended session after the 4 p.m. close. Candel fell 39.09% to $5.11 in that session on Nov. 12. In pre-market trading on Nov. 13 (before the 9:30 a.m. open) it was at $5.25, up 2.73% from that after-hours close, on 471,580 shares. The pre-market low was $5.00.

In the regular session on Nov. 13, shares rose 18.1% from the pre-market close to $6.20. The range ran from $5.19 to $6.63, on 5.85 million shares, about 5.5 times the 10-day average pace. In after-hours trading that evening the stock was at $6.15, down 0.81%, on 84,135 shares.

The slide began before the filings. Shares fell 9.0% in the regular session on Nov. 12, to $8.39, and it is not clear what drove that drop. Before that, the stock had a high of $9.84 on Nov. 9, closed at $9.49, $9.35 and $9.22 on Nov. 9, 10 and 11, and had a low of $7.70 on Oct. 26.

What the filings said

A BLA is the formal request for FDA approval to market a biologic drug. Candel said the mid-2027 plan is pending the result of its dialogue with the FDA. A law firm release later described the announcement as a delay to mid-2027.

The prospectus supplement says Candel had already sold the full $50 million available under its earlier at-the-market program with Jefferies LLC. In an at-the-market offering, a company sells new shares into the open market at prevailing prices. The new agreement allows up to $50 million more, against a market value of about $460 million, with a 3.0% commission to Jefferies. Jefferies is not required to sell any specific amount. The prospectus cites the $9.22 close on Nov. 11.

Candel's third-quarter results came in better than analysts had expected: a loss of $0.28 per share against an estimate of $0.35. The stock fell regardless.

Losses widen while cash stretches into 2028

  • Cash and equivalents were $203.1 million on Sept. 30, which the company said funds its operating plan into the second quarter of 2028.
  • Net loss was $21.9 million, against $11.3 million a year earlier.
  • Research and development expense rose to $15.6 million from $8.5 million, on clinical trial, manufacturing and employee costs.
  • General and administrative expense rose to $7.4 million from $4.7 million, partly on commercial readiness costs.

Candel said validation batches made at its contract manufacturer are in testing and are intended for commercial use, pending BLA approval. It also presented immune-response data from a phase 2 prostate trial at the Society for Immunotherapy of Cancer meeting in November. The float (shares available to trade) is about 65.31 million shares.

A law firm opens an inquiry

On Nov. 13, Block & Leviton announced an investigation into whether Candel misled investors about BLA readiness, including manufacturing process validation and submission timelines. The firm said it is seeking to represent investors who may have suffered losses.

What comes next

  • The FDA dialogue that, according to Candel, will determine the mid-2027 BLA submission.
  • Whether Candel sells shares under the new $50 million program.
  • Biodistribution and shedding data from the ongoing phase 2 prostate trial, which the company said remain on track.

Bottom line

Candel moved its BLA target to mid-2027 and renewed its stock-sale capacity on the same evening. Shares closed Nov. 13 at $6.20, after falling to $5.11 in the first after-hours reaction. The company has cash into the second quarter of 2028, and its filing date now depends on talks with the FDA.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.

Read the original report